

Brief Report



OPEN ACCESS

Received: Aug 25, 2023

Revised: Oct 10, 2023

Accepted: Oct 12, 2023

Published online: Nov 6, 2023

Correspondence to

Menno Hoekstra

Division of Systems Pharmacology and
Pharmacy, Leiden Academic Centre for Drug
Research, Leiden University, Einsteinweg 55,
2333 CC Leiden, The Netherlands.
Email: hoekstra@lacdr.leidenuniv.nl

Copyright © 2024 The Korean Society of Lipid
and Atherosclerosis.

This is an Open Access article distributed
under the terms of the Creative Commons
Attribution Non-Commercial License ([https://
creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/))
which permits unrestricted non-commercial
use, distribution, and reproduction in any
medium, provided the original work is properly
cited.

ORCID iDs

Menno Hoekstra

<https://orcid.org/0000-0001-7463-2893>

Zhengzheng Zhang

<https://orcid.org/0000-0002-0537-3506>

Peter W. Lindenburg

<https://orcid.org/0000-0002-6034-218X>

Miranda Van Eck

<https://orcid.org/0000-0003-3936-3194>

Funding

None.

Conflict of Interest

The authors have no conflicts of interest to
declare.

<https://e-jla.org>

Scavenger Receptor BI Deficiency in Mice Is Associated With Plasma Ceramide and Sphingomyelin Accumulation and a Reduced Cholesteryl Ester Fatty Acid Length and Unsaturation Degree

Menno Hoekstra ^{1,2} **Zhengzheng Zhang** ³ **Peter W. Lindenburg** ⁴
Miranda Van Eck ^{1,2}

¹Division of Systems Pharmacology and Pharmacy, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands

²Pharmacy Leiden, Leiden, The Netherlands

³Metabolomics and Analytics Center, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands

⁴Research Group Metabolomics, Faculty Science & Technology, University of Applied Sciences Leiden, Hogeschool Leiden, Leiden, The Netherlands

ABSTRACT

Objective: Scavenger receptor class B type I (SR-BI) is primarily known for its role in the selective uptake of cholesteryl esters (CEs) from high-density lipoproteins (HDLs). Here we investigated whether SR-BI deficiency is associated with other potentially relevant changes in the plasma lipidome than the established effect of HDL-cholesterol elevation.

Methods: Targeted ultra-high-performance liquid chromatography-tandem mass spectrometry was utilized to measure lipid species in plasma from female wild-type and SR-BI knockout mice.

Results: SR-BI deficiency was associated with a reduction in the average CE fatty acid length (-2% ; $p<0.001$) and degree of CE fatty acid unsaturation (-18% ; $p<0.001$) due to a relative shift from longer, polyunsaturated CE species CE (20:4), CE (20:5), and CE (22:6) towards the mono-unsaturated CE (18:1) species. Sphingomyelin (SM) levels were 64% higher ($p<0.001$) in SR-BI knockout mice without a parallel change in (lyso)phosphatidylcholine (LPC) concentrations, resulting in an increase in the SM/LPC ratio from 0.102 ± 0.005 to 0.163 ± 0.003 ($p<0.001$). In addition, lower LPC lengths (-5% ; $p<0.05$) and fatty acid unsaturation degrees (-20% ; $p<0.01$) were detected in SR-BI knockout mice. Furthermore, SR-BI deficiency was associated with a 4.7-fold increase ($p<0.001$) in total plasma ceramide (Cer) levels, with a marked >9 -fold rise ($p<0.001$) in Cer (d18:1/24:1) concentrations.

Conclusion: We have shown that SR-BI deficiency in mice not only impacts the CE concentrations, length, and saturation index within the plasma compartment, but is also associated with plasma accumulation of several Cer and SM species that may contribute to the development of specific hematological and metabolic (disease) phenotypes previously detected in SR-BI knockout mice.

Keywords: Scavenger receptor BI; Ceramides; Sphingolipids; Cholesteryl esters; Lipids

Data Availability Statement

All data generated or analyzed during this study are included in this published article.

Author Contributions

Conceptualization: Hoekstra M, Zhang Z; Formal analysis: Hoekstra M, Zhang Z; Methodology: Zhang Z, Lindenburg PW; Writing - original draft: Hoekstra M; Writing - review & editing: Lindenburg PW, Van Eck M.

INTRODUCTION

Scavenger receptor class B type I (SR-BI/SCARB1) is an important player in the maintenance of total body homeostasis as judged from the observation that genetic disruption of its functionality is associated with multiple pathologies. Human heterozygous carriers of the loss-of-function P297S mutation in the SCARB1 gene exhibit increased plasma high-density lipoprotein (HDL)-cholesterol levels, an altered platelet morphology and function, and a diminished adrenal steroidogenic capacity.¹ The presence of the human SCARB1 P376L variant, that impairs posttranslational processing of SR-BI, is also associated with relatively high plasma HDL-cholesterol levels as well as an increased susceptibility for the development of atherosclerotic cardiovascular disease.² SR-BI deficiency in mice similarly associates with plasma HDL-cholesterol accumulation, adrenal glucocorticoid insufficiency, an increased atherosclerosis susceptibility, and thrombocytopenia.³⁻⁹ Furthermore, SR-BI knockout mice are anemic and display a diminished epidermal skin barrier function.^{8,10}

SR-BI is predominantly known for its essential role in the selective uptake of cholesteryl esters (CEs) from HDL, i.e. the removal of HDL-associated CEs from the plasma compartment without parallel cellular uptake of the HDL protein component.¹¹ However, our recent findings have revealed that total body SR-BI deficiency in mice is also associated with marked changes in ceramide (Cer) and fatty acid levels within the skin.¹⁰ *In vitro* studies have suggested that SR-BI is able to facilitate the cellular uptake of Cers and fatty acid as well as phosphatidylcholine (PC) and sphingomyelin (SM) via both selective and non-selective mechanisms.¹²⁻¹⁵ Notably, Cers and fatty acids are bioactive molecules involved in a variety of physiological processes, including cellular and tissue metabolism, cell growth, migration, differentiation, and senescence.^{16,17} It can therefore be hypothesized that total body SR-BI deficiency is associated with other significant changes in the plasma lipidome than the established effect on HDL-cholesterol levels that may potentially also contribute to the development of the different (disease) phenotypes detected in SR-BI deficient human subjects and mice. To demonstrate this hypothesis, in this study we quantified the state-of-the-art lipid analysis level of CEs, Cers, (lyso)phosphatidylcholines (LPCs), and SMs in plasma samples obtained from SR-BI knockout mice.

MATERIALS AND METHODS**1. Mice**

Age-matched C57BL/6 wild-type mice (n=5) and SR-BI knockout mice (n=5) were obtained through in-house breeding and fed a regular chow, low-fat diet ad libitum. Female mice were specifically used for this study as it has become evident from previous experiments that SR-BI deficiency-associated pathologies such as the increased susceptibility to atherosclerotic lesion development and higher bone formation can only be detected in female SR-BI knockout mice and/or are more extremely present in female mice than in their male counterparts.^{9,18,19} At 12 weeks of age, mice were anesthetized with a mix of xylazine (70 mg/kg), ketamine (350 mg/kg), and atropine (1.8 mg/kg) and sacrificed by orbital exsanguination. Orbital blood was collected in ethylenediaminetetraacetic acid-containing tubes and centrifuged for 10 minutes at 6,000 rpm to acquire plasma. Plasma samples were stored at -20°C and left otherwise untouched until they were utilized for lipid profiling. The experiment was performed in accordance with the ARRIVE guidelines and approved by the Dutch Central Commission for Animal experimentation (Centrale Commissie voor

Dierproeven) according to the Dutch Law on laboratory animal experimentation and the EU Directive 2010/63/EU.

2. Plasma lipid profiling

Targeted metabolomic analysis was performed using previously published standard operating procedures.²⁰⁻²³ Ten microliters of each individual plasma sample were spiked with calibration and internal standards and extracted using isopropyl alcohol. Samples were analyzed using an ACQUITY ultra-high-performance liquid chromatography system (Waters Chromatography Europe BV) coupled to a quadrupole time-of-flight (SCIEX Triple TOF 6600) for the presence of the CE, Cer, LPC, and SM species displayed in **Table 1**. Quality control (QC) procedures were used to monitor the data acquisition quality by adding QC samples that were prepared by pooling equal volumes of each study sample. An in-house developed tool, mzQuality, was used to correct for batch effects and highlight metabolites with high technical noise, calculated as the relative standard deviation observed in the QC samples (QC RSD).

3. Statistical analysis

Statistical analysis was performed using Graphpad Prism software (<http://www.graphpad.com>). Data were log-transformed before subsequent statistical analysis in order to obtain a normal data distribution. The significance of differences was calculated using a two-tailed unpaired *t*-test or two-way analysis of variance with Bonferroni post-test where appropriate. Probability values less than 0.05 were considered significant.

RESULTS

Five CE variants out of the six species measured could be reliably detected, i.e. with a QC RSD value <15, in plasma samples obtained from female normolipidemic C57BL/6 wild-type mice and the age-matched female SR-BI knockout mice. In accordance with previous findings of Furbee et al.,²⁴ CE (18:2) and CE (20:4) were the most highly present CE species found in plasma obtained from wild-type mice (**Fig. 1A**). SR-BI deficiency was associated with a significant reduction in the average CE fatty acid length (-2%; $p < 0.001$; **Fig. 1B**), favoring 18

Table 1. Individual species included in the targeted plasma lipid profiling

CEs	SMs	LPCs	LPCs	PCs	Cers
CE (18:1)	SM (d18:1/16:1)	LPC (14:0)	PC (34:2)	PC (40:6)	Cer (d18:0/22:0)
CE (18:2)	SM (d18:1/18:0)	LPC (16:0)	PC (34:3)	PC (40:7)	Cer (d18:0/23:0)
CE (18:3)	SM (d18:1/18:1)	LPC (16:1)	PC (34:4)	PC (40:8)	Cer (d18:0/24:0)
CE (20:4)	SM (d18:1/18:2)	LPC (18:0)	PC (36:1)	PC (O-34:1)	Cer (d18:1/16:0)
CE (20:5)	SM (d18:1/20:0)	LPC (18:1)	PC (36:1)	PC (O-34:2)	Cer (d18:1/18:0)
CE (22:6)	SM (d18:1/20:1)	LPC (18:2)	PC (36:2)	PC (O-34:3)	Cer (d18:1/20:0)
	SM (d18:1/21:0)	LPC (18:3)	PC (36:3)	PC (O-36:2)	Cer (d18:1/22:0)
	SM (d18:1/22:0)	LPC (20:3)	PC (36:4)	PC (O-36:3)	Cer (d18:1/22:1)
	SM (d18:1/22:1)	LPC (20:4)	PC (36:5)	PC (O-36:5)	Cer (d18:1/23:0)
	SM (d18:1/23:0)	LPC (20:5)	PC (36:6)	PC (O-36:6)	Cer (d18:1/24:0)
	SM (d18:1/23:1)	LPC (22:6)	PC (38:2)	PC (O-38:4)	Cer (d18:1/24:1)
	SM (d18:1/24:0)	LPC (O-16:0)	PC (38:3)	PC (O-38:5)	
	SM (d18:1/24:1)	LPC (O-16:1)	PC (38:4)	PC (O-38:6)	
	SM (d18:1/24:2)	LPC (O-18:1)	PC (38:5)	PC (O-38:7)	
	SM (d18:1/25:0)	PC (32:0)	PC (38:6)	PC (O-40:6)	
	SM (d18:1/25:1)	PC (32:1)	PC (38:7)	PC (O-42:6)	
		PC (32:2)	PC (40:4)	PC (O-44:5)	
		PC (34:1)	PC (40:5)		

CE, cholesteryl ester; SM, sphingomyelin; LPC, (lyso)phosphatidylcholine; Cer, ceramide; PC, phosphatidylcholine.

SR-BI Deficiency Associated Lipidome Changes




Fig. 1. Effect of SR-BI deficiency on the plasma CE pool. Levels of individual CE species (A) and average CE fatty acid lengths (B) and unsaturation indices (C) in plasma from female WT mice (n=5; white bars) and age-matched female SR-BI KO mice (n=5; black bars). CE, cholesteryl ester; WT, wild-type; SR-BI KO, scavenger receptor class B type I knockout. * $p < 0.05$, † $p < 0.001$ vs. WT.

carbon over 20 and 22 carbon fatty acid CE species. As depicted in **Fig. 1C**, SR-BI deficiency was also associated with a reduced degree of CE fatty acid unsaturation (-18% ; $p < 0.001$), given that concentrations of longer, polyunsaturated CE species CE (20:4), CE (20:5), and CE (22:6) were significantly reduced in the context of a minor increase in mono-unsaturated CE (18:1) levels (**Fig. 1A**).

Earlier findings from Lee et al.²⁵ have suggested that loss of SR-BI functionality is associated with an enrichment of HDL particles with SM, leading to an increase in the plasma SM/PC ratio. In accordance, in our experimental setting we also found plasma total SM levels to be significantly elevated ($+64\%$; $p < 0.001$; **Fig. 2A**) in response to genetic SR-BI deficiency, without a parallel change in LPC concentrations (**Fig. 3A**). As a result, the plasma SM/LPC ratio increased from 0.102 ± 0.005 in wild-type mice to 0.163 ± 0.003 in SR-BI knockout mice ($p < 0.001$). The increase in total SM levels associated with SR-BI deficiency could be attributed to accumulation of SM (d18:1/14:0) ($+29\%$; $p < 0.05$), SM (d18:1/16:0) ($+66\%$; $p < 0.001$), SM (d18:1/18:0) ($+78\%$; $p < 0.001$), SM (d18:1/18:2) ($+50\%$; $p < 0.001$), SM (d18:1/22:0) ($+48\%$; $p < 0.001$), SM (d18:1/24:1) ($+85\%$; $p < 0.001$), and SM (d18:1/24:2) ($+64\%$; $p < 0.001$) within the plasma compartment (**Fig. 2D**). In contrast, plasma levels of SM(d18:1/25:1) were relatively decreased in SR-BI knockout mice as compared to those found in wild-type mice (-44% ; $p < 0.001$) (**Fig. 2D**). Overall, the average SM fatty acid length (**Fig. 2B**) and saturation index (**Fig. 2C**) were not influenced by the SR-BI genotype. In contrast, since levels of PC (O-42:6), PC (O-44:5) and various highly unsaturated PC38 and PC40 species were significantly lower and those of LPC (O-16:0), LPC (O-18:1), and PC32 and PCO34 variants higher in plasma from SR-BI knockout mice as compared to that of wild-type mice (**Fig. 3D**), SR-BI deficiency was associated with an average lower LPC length (-5% ; $p < 0.05$; **Fig. 3B**) and degree of fatty acid unsaturation (-20% ; $p < 0.01$; **Fig. 3C**).

All 11 Cer species available on the analysis platform could be readily detected in the plasma samples from our wild-type and SR-BI knockout mice (QC RSD range: 3.9–7.8). However, as evident from **Fig. 4A**, SR-BI deficiency was associated with a marked 4.7-fold increase ($p < 0.001$) in total plasma Cer levels. Apart from those of Cer (d18:1/22:1), whose levels remained unaffected, amounts of the individual Cer variants were increased by 1.9-fold, i.e. Cer (d18:1/18:0), or more in plasma from SR-BI knockout mice as compared to that of wild-type mice (**Fig. 4D**). Notably, a striking >9 -fold rise ($p < 0.001$) in the plasma concentration

SR-BI Deficiency Associated Lipidome Changes




Fig. 2. Effect of SR-BI deficiency on the plasma SM pool. Total SM levels (A), average SM fatty acid lengths (B), unsaturation indices (C), and levels of individual SM variants (D) in plasma from female WT mice (n=5; white bars) and age-matched female SR-BI KO mice (n=5; black bars) (D). SM, sphingomyelin; WT, wild-type; SR-BI KO, scavenger receptor class B type I knockout. **p*<0.05, ⁺*p*<0.01, [‡]*p*<0.001 vs. WT.

of the highly present unsaturated Cer species Cer (d18:1/24:1) was detected in response to the genetic lack of SR-BI (**Fig. 4D**). As a result, the average degree of fatty acid unsaturation within the Cer pool was increased by 71% (*p*<0.001) (**Fig. 4C**), whilst also a minor, but significant increase in the Cer fatty acid length was detected (+3%; *p*<0.001; **Fig. 4B**).

DISCUSSION

In the current study we tested the hypothesis that total body SR-BI deficiency is associated with additional pathological changes in the plasma lipidome than the firmly established cholesterol raising effect. We have shown that scavenger receptor BI deficiency in mice is

SR-BI Deficiency Associated Lipidome Changes




Fig. 3. Effect of SR-BI deficiency on the plasma LPC pool. Total LPC levels (A), average LPC fatty acid lengths (B) and unsaturation indices (C), and levels of individual LPC variants (D) in plasma from female WT mice (n=5; white bars) and age-matched female SR-BI KO mice (n=5; black bars) (D). LPC, (lyso)phosphatidylcholine; WT, wild-type; SR-BI KO, scavenger receptor class B type I knockout; PC, phosphatidylcholine.

*p<0.05, †p<0.01, ‡p<0.001 vs. WT.

associated with plasma Cer and SM accumulation and a reduced CE fatty acid length and unsaturation degree.

The observation that SR-BI deficiency is associated with a reduction in the CE length and unsaturation index concurs with the earlier finding from Lee et al.²⁵ that the activity of the CE (20:4) and CE (22:6)-producing enzyme lecithin-cholesterol acyltransferase (LCAT) is decreased in SR-BI knockout mice. Thacker et al.²⁶ have shown that normalization of LCAT functionality in SR-BI knockout mice through transgenic LCAT overexpression is able to reverse the SR-BI deficiency associated decrease in the circulating blood platelet concentration and increase in atherosclerosis susceptibility. Given that findings from Martins Cardoso et al.¹⁰ have suggested that the accumulation of CE (18:1) is likely underlying the SR-BI deficiency-associated change in skin lipid levels and skin barrier disruption, it will be of interest to investigate whether skin morphology and functionality is also normalized in LCAT overexpressing SR-BI knockout mice.

The combined accumulation of SMs and Cers in the plasma compartment of SR-BI knockout mice fuels the notion, derived from *in vitro* studies by Urban et al.²⁷ and Li et al.,¹² that SR-BI is an important player in the cellular uptake of (HDL particle-associated) SMs and Cers. *In*

SR-BI Deficiency Associated Lipidome Changes




Fig. 4. Effect of SR-BI deficiency on the plasma Cer pool. Total Cer levels (A), average Cer fatty acid lengths (B) and unsaturation indices (C), and levels of individual Cer variants (D) in plasma from female WT mice (n=5; white bars) and age-matched female SR-BI KO mice (n=5; black bars). Cer, ceramide; WT, wild-type; SR-BI KO, scavenger receptor class B type I knockout.

*p<0.001 vs. WT.

in vitro studies have suggested that only a limited amount of SM is selectively taken up into cells by SR-BI.¹⁴ However, since levels of SM (d18:1/24:1) are substantially elevated in plasma of SR-BI knockout mice (+85% vs. wild-type plasma), we anticipate that the relative rates of selective and non-selective lipid uptake may differ between *in vitro* cultured cells and the *in vivo* setting. In this context, it good to appreciate that findings from Tsukamoto et al.²⁸ have already highlighted that significant differences exist in the mechanism behind PDZ domain containing adaptor protein PDZK1-dependent expression of SR-BI (and associated CE uptake) between cultured cells and hepatocytes *in vivo*.

High levels of Cers have previously been associated with induction of oxidative stress i.e. the production of reactive oxygen species.²⁹ Cer accumulation may therefore contribute to the

increased oxidative stress status previously detected in SR-BI knockout mice.³⁰ In addition, increased Cer-induced eryptosis, i.e. Cer-mediated changes in membrane permeability and concomitant suicidal death of erythrocytosis,³¹ can be considered a potential driver of the SR-BI deficiency-associated increase in erythrocyte turnover and anemia development.⁸ Given that findings from Yamaguchi et al.³² have suggested that a higher erythrocyte SM content is associated with an increased hypotonic hemolysis rate, the plasma SM accumulation may potentially also contribute to the SR-BI deficiency-associated anemia development. Studies using SM synthase 2 deficiency platelets have indicated that SMs facilitate the aggregation of platelets in response to thrombin and collagen.³³ Plasma SM accumulation in SR-BI knockout mice would thus be expected to stimulate platelet aggregation. However, Simon and Gear³⁴ have shown—using isolated human platelets—that the cell-permeable short-chain analogue C2-Cer causes the formation of irregular pseudopodia, leading to a diminished platelet aggregation potential. We therefore anticipate that the previously observed decrease in the ability of SR-BI knockout platelets to aggregate^{1,7,35} can be attributed to the fact that the relative impact of SR-BI deficiency on total plasma levels of SMs/platelet activators (1.6-fold) is much less pronounced than that on plasma levels of Cers/platelet activity inhibitors (4.7-fold). Studies in rats have shown that an increase in hepatic Cer stores is a phenomenon rapidly detected in response to infusion with lard oil.³⁶ An impaired ability of SR-BI deficient hepatocytes to take up Cers may potentially also underlie the protection of total body SR-BI knockout mice against high fat (lard) diet-induced fatty liver development.³⁷

An interesting observation in our study was that levels of Cer (d18:1/24:1) were >9-fold elevated in plasma of SR-BI knockout mice. High plasma levels of Cer (d18:1/24:1) have consistently been associated with a higher systemic inflammatory state and an increased atherosclerotic cardiovascular disease risk in humans.³⁸⁻⁴¹ One could thus perhaps anticipate that chow-fed SR-BI knockout mice also display a high susceptibility to develop atherosclerotic lesions. However, to our knowledge, no atherosclerotic lesions have ever been detected in regular chow diet-fed (aged) SR-BI knockout mice. We therefore perceive the increase in Cer (d18:1/24:1) concentrations rather a signal that SR-BI knockout mice exhibit a higher baseline inflammatory state. This corroborates our earlier findings that liver macrophages (i.e. Kupffer cells) from chow diet-fed SR-BI knockout mice exhibit a more inflammatory phenotype as exemplified by relatively high gene expression levels of the pro-inflammatory cytokines interleukin-6 and tumor necrosis factor- α .⁴ Dihydroceramide desaturase 1 (DEGS1) appears to play an essential role in the synthesis of Cer (d18:1/24:1) as the L175Q loss-of-function mutation in DEGS1 in humans is associated with a reduction in plasma Cer (d18:1/24:1) levels in the context of elevated Cer (d18:1/24:0) levels.⁴² Dogra et al.⁴³ have shown that pro-inflammatory polarization of macrophages is associated with an increase in DEGS1 expression. These combined findings imply that the increase in plasma Cer (d18:1/24:1) levels observed in SR-BI knockout mice may actually be secondary to an increase in the number and/or activity of pro-inflammatory macrophages. To provide proof for an important contribution of macrophages to plasma Cer (d18:1/24:1) levels and uncover the actual relevance for atherosclerosis susceptibility, selective elimination of DEGS1 function in macrophages in SR-BI knockout mice as well as atherosclerosis-susceptible hypercholesterolemic mice, i.e. low-density lipoprotein receptor knockout or apolipoprotein E knockout mice, should be pursued.

In conclusion, we have shown that SR-BI deficiency in mice not only impacts the CE concentrations, length, and saturation index within the plasma compartment, but is also associated with plasma accumulation of several Cer and SM species that may contribute to the

development of specific hematological and metabolic (disease) phenotypes previously detected in SR-BI knockout mice. A strong point of our findings is that we have been able to complement earlier *in vitro* evidence with *in vivo* proof for the role of SR-BI as mediator of SM and Cer uptake. Furthermore, these novel observations highlight that it is of interest to determine the impact of plasma Cer level normalization on SR-BI deficiency-associated phenotypes. Given that the enlarged, lipid-rich HDL particles from SR-BI knockout mice are commonly regarded as being less functional,⁴⁴ the individual changes in the plasma lipidome detected in these mice can potentially be used as novel biomarkers for HDL dysfunction in the human clinical (atherosclerotic cardiovascular disease) setting. In this context, it will be important to further validate the relevance of our findings in mouse models with a more human-like lipoprotein profile, i.e. in mice that do express human CE transfer protein, as well as in human subjects carrying a functional mutation in the SR-BI gene. In follow-up studies special attention should also be given to the potential impact of sex on genotype-associated changes in the HDL/plasma lipidome, i.e. the current study was limited to the use of female mice, since significant SR-BI gene by sex interaction has been seen before in the clinical setting.⁴⁵ In addition, in future studies it will be important to monitor the plasma lipidome and composition and function of blood cells in the same test animals/human subjects to provide more clear evidence for a causal relationship between changes in the two individual parameters.

REFERENCES

1. Vergeer M, Korporaal SJ, Franssen R, Meurs I, Out R, Hovingh GK, et al. Genetic variant of the scavenger receptor BI in humans. *N Engl J Med* 2011;364:136-145. [PUBMED](#) | [CROSSREF](#)
2. Zanoni P, Khetarpal SA, Larach DB, Hancock-Cerutti WF, Millar JS, Cuchel M, et al. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. *Science* 2016;351:1166-1171. [PUBMED](#) | [CROSSREF](#)
3. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. *Science* 1996;271:518-520. [PUBMED](#) | [CROSSREF](#)
4. Hoekstra M, Meurs I, Koenders M, Out R, Hildebrand RB, Kruijt JK, et al. Absence of HDL cholesteryl ester uptake in mice via SR-BI impairs an adequate adrenal glucocorticoid-mediated stress response to fasting. *J Lipid Res* 2008;49:738-745. [PUBMED](#) | [CROSSREF](#)
5. Hoekstra M, Ye D, Hildebrand RB, Zhao Y, Lammers B, Stitzinger M, et al. Scavenger receptor class B type I-mediated uptake of serum cholesterol is essential for optimal adrenal glucocorticoid production. *J Lipid Res* 2009;50:1039-1046. [PUBMED](#) | [CROSSREF](#)
6. Van Eck M, Twisk J, Hoekstra M, Van Rij BT, Van der Lans CA, Bos IS, et al. Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver. *J Biol Chem* 2003;278:23699-23705. [PUBMED](#) | [CROSSREF](#)
7. Korporaal SJ, Meurs I, Hauer AD, Hildebrand RB, Hoekstra M, Cate HT, et al. Deletion of the high-density lipoprotein receptor scavenger receptor BI in mice modulates thrombosis susceptibility and indirectly affects platelet function by elevation of plasma free cholesterol. *Arterioscler Thromb Vasc Biol* 2011;31:34-42. [PUBMED](#) | [CROSSREF](#)
8. Meurs I, Hoekstra M, van Wanrooij EJ, Hildebrand RB, Kuiper J, Kuipers F, et al. HDL cholesterol levels are an important factor for determining the lifespan of erythrocytes. *Exp Hematol* 2005;33:1309-1319. [PUBMED](#) | [CROSSREF](#)
9. Harder C, Lau P, Meng A, Whitman SC, McPherson R. Cholesteryl ester transfer protein (CETP) expression protects against diet induced atherosclerosis in SR-BI deficient mice. *Arterioscler Thromb Vasc Biol* 2007;27:858-864. [PUBMED](#) | [CROSSREF](#)
10. Martins Cardoso R, Creemers E, Absalah S, Hoekstra M, Gooris GS, Bouwstra JA, et al. Hyperalphalipoproteinemic scavenger receptor BI knockout mice exhibit a disrupted epidermal lipid barrier. *Biochim Biophys Acta Mol Cell Biol Lipids* 2020;1865:158592. [PUBMED](#) | [CROSSREF](#)
11. Out R, Hoekstra M, Spijkers JA, Kruijt JK, van Eck M, Bos IS, et al. Scavenger receptor class B type I is solely responsible for the selective uptake of cholesteryl esters from HDL by the liver and the adrenals in mice. *J Lipid Res* 2004;45:2088-2095. [PUBMED](#) | [CROSSREF](#)

12. Li XA, Titlow WB, Jackson BA, Giltiay N, Nikolova-Karakashian M, Uittenbogaard A, et al. High density lipoprotein binding to scavenger receptor, Class B, type I activates endothelial nitric-oxide synthase in a ceramide-dependent manner. *J Biol Chem* 2002;277:11058-11063. [PUBMED](#) | [CROSSREF](#)
13. Wang W, Yan Z, Hu J, Shen WJ, Azhar S, Kraemer FB. Scavenger receptor class B, type 1 facilitates cellular fatty acid uptake. *Biochim Biophys Acta Mol Cell Biol Lipids* 2020;1865:158554. [PUBMED](#) | [CROSSREF](#)
14. Rodriguez VV, Thuahnai ST, Temel RE, Lund-Katz S, Phillips MC, Williams DL. Mechanism of scavenger receptor class B type I-mediated selective uptake of cholesteryl esters from high density lipoprotein to adrenal cells. *J Biol Chem* 1999;274:20344-20350. [PUBMED](#) | [CROSSREF](#)
15. Thuahnai ST, Lund-Katz S, Williams DL, Phillips MC. Scavenger receptor class B, type I-mediated uptake of various lipids into cells. Influence of the nature of the donor particle interaction with the receptor. *J Biol Chem* 2001;276:43801-43808. [PUBMED](#) | [CROSSREF](#)
16. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. *Nat Rev Mol Cell Biol* 2008;9:139-150. [PUBMED](#) | [CROSSREF](#)
17. Calder PC. Functional roles of fatty acids and their effects on human health. *JPEN J Parenter Enteral Nutr* 2015;39:18S-32S. [PUBMED](#) | [CROSSREF](#)
18. Hildebrand RB, Lammers B, Meurs I, Korporeal SJ, De Haan W, Zhao Y, et al. Restoration of high-density lipoprotein levels by cholesteryl ester transfer protein expression in scavenger receptor class B type I (SR-BI) knockout mice does not normalize pathologies associated with SR-BI deficiency. *Arterioscler Thromb Vasc Biol* 2010;30:1439-1445. [PUBMED](#) | [CROSSREF](#)
19. Martineau C, Martin-Falstrault L, Brissette L, Moreau R. Gender- and region-specific alterations in bone metabolism in Scarb1-null female mice. *J Endocrinol* 2014;222:277-288. [PUBMED](#) | [CROSSREF](#)
20. Noga MJ, Dane A, Shi S, Attali A, van Aken H, Suidgeest E, et al. Metabolomics of cerebrospinal fluid reveals changes in the central nervous system metabolism in a rat model of multiple sclerosis. *Metabolomics* 2012;8:253-263. [PUBMED](#) | [CROSSREF](#)
21. Schoeman JC, Harms AC, van Weeghel M, Berger R, Vreeken RJ, Hankemeier T. Development and application of a UHPLC-MS/MS metabolomics based comprehensive systemic and tissue-specific screening method for inflammatory, oxidative and nitrosative stress. *Anal Bioanal Chem* 2018;410:2551-2568. [PUBMED](#) | [CROSSREF](#)
22. Hu C, van Dommelen J, van der Heijden R, Spijksma G, Reijmers TH, Wang M, et al. RPLC-ion-trap-FTMS method for lipid profiling of plasma: method validation and application to p53 mutant mouse model. *J Proteome Res* 2008;7:4982-4991. [PUBMED](#) | [CROSSREF](#)
23. Zhang Z, Duri K, Duisters K LW, Schoeman JC, Chandiwana P, Lindenburg P, et al. Altered methionine-sulfone levels are associated with impaired growth in HIV-exposed-uninfected children. *AIDS* 2023;37:1367-1376. [PUBMED](#) | [CROSSREF](#)
24. Furbee JW Jr, Francone O, Parks JS. Alteration of plasma HDL cholesteryl ester composition with transgenic expression of a point mutation (E149A) of human LCAT. *J Lipid Res* 2001;42:1626-1635. [PUBMED](#) | [CROSSREF](#)
25. Lee JY, Badeau RM, Mulya A, Boudyguina E, Gebre AK, Smith TL, et al. Functional LCAT deficiency in human apolipoprotein A-I transgenic, SR-BI knockout mice. *J Lipid Res* 2007;48:1052-1061. [PUBMED](#) | [CROSSREF](#)
26. Thacker SG, Rousset X, Esmail S, Zarzour A, Jin X, Collins HL, et al. Increased plasma cholesterol esterification by LCAT reduces diet-induced atherosclerosis in SR-BI knockout mice. *J Lipid Res* 2015;56:1282-1295. [PUBMED](#) | [CROSSREF](#)
27. Urban S, Zieseniss S, Werder M, Hauser H, Budzinski R, Engelmann B. Scavenger receptor BI transfers major lipoprotein-associated phospholipids into the cells. *J Biol Chem* 2000;275:33409-33415. [PUBMED](#) | [CROSSREF](#)
28. Tsukamoto K, Buck L, Inman W, Griffith L, Kocher O, Krieger M. Challenges in using cultured primary rodent hepatocytes or cell lines to study hepatic HDL receptor SR-BI regulation by its cytoplasmic adaptor PDZK1. *PLoS One* 2013;8:e69725. [PUBMED](#) | [CROSSREF](#)
29. García-Ruiz C, Colell A, Mari M, Morales A, Fernández-Checa JC. Direct effect of ceramide on the mitochondrial electron transport chain leads to generation of reactive oxygen species. Role of mitochondrial glutathione. *J Biol Chem* 1997;272:11369-11377. [PUBMED](#) | [CROSSREF](#)
30. Van Eck M, Hoekstra M, Hildebrand RB, Yaong Y, Stengel D, Kruijt JK, et al. Increased oxidative stress in scavenger receptor BI knockout mice with dysfunctional HDL. *Arterioscler Thromb Vasc Biol* 2007;27:2413-2419. [PUBMED](#) | [CROSSREF](#)
31. Lang E, Bissinger R, Gulbins E, Lang F. Ceramide in the regulation of eryptosis, the suicidal erythrocyte death. *Apoptosis* 2015;20:758-767. [PUBMED](#) | [CROSSREF](#)
32. Yamaguchi T, Hirakawa R, Ochiai H. Correlation between sphingomyelin and the membrane stability of mammalian erythrocytes. *Comp Biochem Physiol B Biochem Mol Biol* 2023;265:110833. [PUBMED](#) | [CROSSREF](#)

33. Guo Y, Chang L, Zhang G, Gao Z, Lin H, Zhang Y, et al. The role of Sphingomyelin synthase 2 (SMS2) in platelet activation and its clinical significance. *Thromb J* 2021;19:27. [PUBMED](#) | [CROSSREF](#)
34. Simon CG Jr, Gear AR. Membrane-destabilizing properties of C2-ceramide may be responsible for its ability to inhibit platelet aggregation. *Biochemistry* 1998;37:2059-2069. [PUBMED](#) | [CROSSREF](#)
35. Dole VS, Matuskova J, Vasile E, Yesilaltay A, Bergmeier W, Bernimoulin M, et al. Thrombocytopenia and platelet abnormalities in high-density lipoprotein receptor-deficient mice. *Arterioscler Thromb Vasc Biol* 2008;28:1111-1116. [PUBMED](#) | [CROSSREF](#)
36. Holland WL, Bikman BT, Wang LP, Yuguang G, Sargent KM, Bulchand S, et al. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. *J Clin Invest* 2011;121:1858-1870. [PUBMED](#) | [CROSSREF](#)
37. Hoekstra M, Ouweneel AB, Price J, van der Geest R, van der Sluis RJ, Geerling JJ, et al. SR-BI deficiency disassociates obesity from hepatic steatosis and glucose intolerance development in high fat diet-fed mice. *J Nutr Biochem* 2021;89:108564. [PUBMED](#) | [CROSSREF](#)
38. Pan W, Li L, Sun M, Wang C, Fang S, Yu B. Plasma ceramides are associated with coronary atherosclerotic burden in patients with ST-segment elevation myocardial infarction. *Int J Cardiol* 2020;320:155-160. [PUBMED](#) | [CROSSREF](#)
39. Mantovani A, Dugo C. Ceramides and risk of major adverse cardiovascular events: a meta-analysis of longitudinal studies. *J Clin Lipidol* 2020;14:176-185. [PUBMED](#) | [CROSSREF](#)
40. Mantovani A, Altomari A, Lunardi G, Bonapace S, Lippi G, Bonnet F, et al. Association between specific plasma ceramides and high-sensitivity C-reactive protein levels in postmenopausal women with type 2 diabetes. *Diabetes Metab* 2020;46:326-330. [PUBMED](#) | [CROSSREF](#)
41. Hilvo M, Vasile VC, Donato LJ, Hurme R, Laaksonen R. Ceramides and ceramide scores: clinical applications for cardiometabolic risk stratification. *Front Endocrinol (Lausanne)* 2020;11:570628. [PUBMED](#) | [CROSSREF](#)
42. Blackburn NB, Michael LF, Meikle PJ, Peralta JM, Mosior M, McAhren S, et al. Rare *DEGSI* variant significantly alters de novo ceramide synthesis pathway. *J Lipid Res* 2019;60:1630-1639. [PUBMED](#) | [CROSSREF](#)
43. Dogra N, Warburton C, McMaster WR. Leishmania major abrogates gamma interferon-induced gene expression in human macrophages from a global perspective. *Infect Immun* 2007;75:3506-3515. [PUBMED](#) | [CROSSREF](#)
44. Cao J, Xu Y, Li F, Shang L, Fan D, Yu H. Protein markers of dysfunctional HDL in scavenger receptor class B type I deficient mice. *J Transl Med* 2018;16:155. [PUBMED](#) | [CROSSREF](#)
45. McCarthy JJ, Somji A, Weiss LA, Steffy B, Vega R, Barrett-Connor E, et al. Polymorphisms of the scavenger receptor class B member 1 are associated with insulin resistance with evidence of gene by sex interaction. *J Clin Endocrinol Metab* 2009;94:1789-1796. [PUBMED](#) | [CROSSREF](#)